MedPath
Found 25 clinical trials|View Analysis
Sort by:

The Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

Not yet recruiting
Conditions
Lung Cancer
First Posted Date
2024-11-18
Last Posted Date
2024-12-16
Lead Sponsor
China-Japan Friendship Hospital
Target Recruit Count
500
Registration Number
NCT06692972

MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer

Phase 2
Recruiting
Conditions
Esophageal Cancer
Interventions
Drug: PD-1 monoclonal antibody consolidation therapy
First Posted Date
2024-07-12
Last Posted Date
2024-08-06
Lead Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Target Recruit Count
102
Registration Number
NCT06498752
Locations
🇨🇳

Cancer hospital, CAMS, Beijing, Beijing, China

Definitive Radiotherapy for Cervical and Upper Thoracic Esophageal Cancer (ChC&UES): A Multi-center Real World Study

Recruiting
Conditions
Esophageal Neoplasm
First Posted Date
2024-07-01
Last Posted Date
2024-07-01
Lead Sponsor
Hebei Medical University Fourth Hospital
Target Recruit Count
2600
Registration Number
NCT06481449
Locations
🇨🇳

Because this study is a response to real-world patient treatment and outcomes, Shijiazhuang, Hebei, China

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Phase 2
Recruiting
Conditions
Non-small Cell Lung Cancer
Interventions
Radiation: definitive radiotherapy
Drug: induction chemo-immunotherapy
Drug: concurrent chemotherapy
Drug: Immunotheapy consolidation
Drug: Thymosin Alpha1
First Posted Date
2023-11-18
Last Posted Date
2023-11-18
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
114
Registration Number
NCT06139419
Locations
🇨🇳

Sun yat-sen university cancer center, Guangzhou, Guangdong, China

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Phase 2
Withdrawn
Conditions
ALK-rearrangement
NSCLC, Stage III
Interventions
First Posted Date
2023-02-08
Last Posted Date
2024-10-08
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
44
Registration Number
NCT05718297
Locations
🇫🇷

CHU Angers, Angers, France

🇫🇷

Caen - CHU, Caen, France

🇫🇷

Hôpital de Marseille, Marseille, France

and more 17 locations

Report of the Survival Outcomes of Patients With Esophageal Cancer After Definitive Radiotherapy in China

Completed
Conditions
Esophageal Neoplasms
Interventions
Radiation: definitive radiotherapy or definitive chemoradiotherapy
First Posted Date
2022-01-18
Last Posted Date
2022-01-18
Lead Sponsor
Chinese Academy of Medical Sciences
Target Recruit Count
3000
Registration Number
NCT05194371
Locations
🇨🇳

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma

Phase 3
Recruiting
Conditions
Locally Advanced Nasopharyngeal Carcinoma
Interventions
Drug: Induction Chemotherapy
Radiation: Definitive Radiotherapy
Drug: Concurrent Chemotherapy
First Posted Date
2021-09-30
Last Posted Date
2021-09-30
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
447
Registration Number
NCT05062005
Locations
🇨🇳

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guang Dong, China

Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL

Phase 2
Not yet recruiting
Conditions
Extranodal NK/T-cell Lymphoma, Nasal Type
Interventions
Drug: Pegaspargase
Drug: Anti-PD-1 monoclonal antibody
Radiation: Definitive intensity-modulated radiotherapy (IMRT)
First Posted Date
2020-12-21
Last Posted Date
2020-12-21
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
30
Registration Number
NCT04676789
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China

A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Phase 3
Recruiting
Conditions
NK/T Cell Lymphoma Nos
Interventions
Drug: Toripalimab
Drug: Pegaspargase
Drug: Gemcitabine
Drug: Oxaliplatin
Radiation: Definitive intensity-modulated radiotherapy (IMRT)
First Posted Date
2020-04-28
Last Posted Date
2020-05-08
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
207
Registration Number
NCT04365036
Locations
🇨🇳

Guangdong General Hospital, Guangzhou, Guangdong, China

The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLC

Phase 2
Terminated
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Other: No metformin
Drug: Metformin
First Posted Date
2019-11-20
Last Posted Date
2021-01-15
Lead Sponsor
ethisch.comite@uza.be
Target Recruit Count
3
Registration Number
NCT04170959
Locations
🇧🇪

University Hospital Antwerp, Edegem, Antwerp, Belgium

© Copyright 2025. All Rights Reserved by MedPath